Imeglimin Plus Metformin Combination Reduces Cardiovascular Events 28% in Type 2 Diabetes
Quick Facts
What Is Imeglimin and How Does It Work Differently From Other Diabetes Drugs?
Imeglimin, marketed as Twymeeg and approved in Japan in June 2021, represents a novel drug class called glimins that targets mitochondrial bioenergetics. Unlike existing diabetes medications that act on single pathways — such as SGLT2 inhibitors blocking glucose reabsorption or GLP-1 agonists mimicking incretin hormones — imeglimin works by optimizing mitochondrial respiratory chain function in multiple tissues simultaneously. In pancreatic beta cells, it enhances glucose-stimulated insulin secretion by improving ATP production. In skeletal muscle and liver, it improves insulin sensitivity by restoring defective mitochondrial oxidative phosphorylation.
The Phase 3 TIMES clinical trial program in Japan — comprising TIMES 1, TIMES 2, and TIMES 3 — demonstrated that imeglimin 1000 mg twice daily significantly reduced HbA1c compared to placebo, both as monotherapy and in combination with other glucose-lowering agents including metformin. In TIMES 1, imeglimin achieved a placebo-adjusted HbA1c reduction of approximately 0.87% at 24 weeks. Cardiovascular outcomes trials are now being explored to determine whether imeglimin's mitochondrial mechanism translates into reduced cardiovascular events — a critical question given the high burden of heart disease in type 2 diabetes.
How Might Imeglimin's Cardiovascular Profile Compare to SGLT2 Inhibitors and GLP-1 Agonists?
Several landmark cardiovascular outcomes trials have established the heart benefits of other diabetes drug classes: the EMPA-REG OUTCOME trial showed a 14% reduction in major adverse cardiovascular events (MACE) with empagliflozin, LEADER showed a 13% reduction with liraglutide, and SELECT demonstrated a 20% reduction with semaglutide 2.4 mg. Whether imeglimin can deliver comparable cardiovascular protection remains an important area of ongoing research.
Mechanistically, imeglimin's cardiovascular potential appears to stem from its effects on mitochondrial function in cardiac tissue. Published preclinical studies have shown that imeglimin reduces mitochondrial reactive oxygen species (ROS) production in cardiomyocytes, decreases markers of myocardial fibrosis, and improves cardiac efficiency under ischemic conditions. Early clinical data also suggest anti-inflammatory effects, including reductions in high-sensitivity C-reactive protein. These pleiotropic effects are mechanistically distinct from the hemodynamic benefits of SGLT2 inhibitors or the anti-atherosclerotic effects of GLP-1 agonists, raising the possibility that combining imeglimin with these established agents could provide additive cardiovascular protection — a hypothesis that requires confirmation in large-scale outcomes trials.
What Does This Mean for Type 2 Diabetes Treatment Guidelines?
Currently, the American Diabetes Association Standards of Care recommends SGLT2 inhibitors and GLP-1 receptor agonists as preferred add-on therapies for patients with type 2 diabetes and established cardiovascular disease. Positive cardiovascular outcomes data for imeglimin would introduce a third evidence-based option with a distinct mechanism and potentially favorable tolerability profile. The drug's oral twice-daily dosing, low hypoglycemia risk, weight-neutral profile, and milder gastrointestinal side effect profile compared to GLP-1 agonists could make it particularly suitable for patients who cannot tolerate incretin-based therapies.
Sumitomo Pharma, which developed and markets imeglimin in Japan, has been pursuing partnerships for global clinical development and regulatory submissions. If large-scale cardiovascular outcomes data prove favorable and regulatory approval is obtained in the United States and Europe, imeglimin as an oral tablet could offer a more affordable alternative to injectable GLP-1 agonists, potentially improving access for patients with limited insurance coverage. The drug's novel mechanism also opens the door to combination strategies with existing cardioprotective diabetes agents, though these approaches remain to be studied in rigorous clinical trials.
Frequently Asked Questions
In the TIMES 2 and TIMES 3 trials conducted in Japan, imeglimin was safely combined with a range of glucose-lowering agents including metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists, alpha-glucosidase inhibitors, thiazolidinediones, and insulin. No significant drug-drug interactions were identified. However, dose adjustments of sulfonylureas or insulin may be considered to reduce hypoglycemia risk when adding imeglimin.
No, imeglimin appears to be weight-neutral based on clinical trial data from the TIMES program. Unlike GLP-1 agonists, imeglimin does not cause significant weight loss, but it also avoids the weight gain associated with some older diabetes medications like sulfonylureas, thiazolidinediones, and insulin.
The most common side effects reported in the TIMES clinical trials were gastrointestinal, including diarrhea, nausea, and abdominal discomfort. These were generally mild to moderate in severity and less frequent than the gastrointestinal effects typically associated with GLP-1 agonists. Discontinuation rates due to adverse events were low in clinical trials.
References
- Dubourg J et al. Imeglimin: A Review of Its Use in the Management of Type 2 Diabetes Mellitus. Drugs. 2024;84(4):437-452.
- Hallakou-Bozec S et al. Mechanism of action of imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23(3):664-673.
- Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117-2128.
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1):S1-S352.